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Abstract
Background: Telomerase is a ribonucleoprotein enzyme that synthesises telomeres after cell
division and maintains chromosomal stability leading to cellular immortalization. Telomerase has
been associated with negative prognostic indicators in some studies. The present study aims to
detect any association between telomerase sub-units: hTERT and hTR and the prognostic
indicators including tumour's size and grade, nodal status and patient's age.
Methods: Tumour samples from 46 patients with primary invasive breast cancer and 3 patients
with benign tumours were collected. RT-PCR analysis was used for the detection of hTR, hTERT,
and PGM1 (as a housekeeping) genes expression.
Results: The expression of hTR and hTERT was found in 31(67.4%) and 38 (82.6%) samples
respectively. We observed a significant association between hTR gene expression and younger age
at diagnosis (p = 0.019) when comparing patients ≤ 40 years with those who are older than 40
years. None of the benign tumours expressed hTR gene. However, the expression of hTERT gene
was revealed in 2 samples.
No significant association between hTR and hTERT expression and tumour's grade, stage and nodal
status was seen.
Conclusion: The expression of hTR and hTERT seems to be independent of tumour's stage. hTR
expression probably plays a greater role in mammary tumourogenesis in younger women (≤ 40
years) and this may have therapeutic implications in the context of hTR targeting strategies.
Background
Telomerase is an RNA dependant DNA polymerase, the
function of which is to synthesise the repetitive nucleotide
sequence (TTAGGG in humans) forming the telomeres at
the end of chromosomes [1]. These telomeres form caps
on the chromosomes that prevent fusion of chromosomal
ends during cell division. The DNA polymerase is unable
to fully replicate the ends of linear DNA and genetic mate-
rial is lost and this can result in chromosomal instability
and cellular senescence. Without telomerase activity, each
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eres and reaching a critical length seems to trigger off cel-
lular apoptosis. Therefore, telomerase activity seems to
stabilize telomeres and to be responsible for compensat-
ing about 65 bp in eukaryotic chromosomal ends, thus,
leading to cellular immortality [1-8] and, may therefore,
be a critical step in carcinogenesis [9,11].
Telomerase is active in 70 – 90% of malignant tissues and
many immortal cell lines, but most somatic cells have no
detectable telomerase activity [5,10,11].
Human telomerase consists of an RNA subunit; human
telomerase RNA (hTR) [12], a protein component
(human telomerase associated protein 1 (hTEP1) [13]
and the catalytic subunit hTERT (human telomerase
reverse transcriptase) [14-16]. Of these subunits telomer-
ase activity requires the presence of hTR, which is the RNA
template for the telomeric repeat, and hTERT, which is the
reverse transcriptase. Furthermore, it is reported that the
induction of hEST2 mRNA expression is required for the
telomerase activation that occurs during cellular immor-
talization and tumor progression. [17]. Several studies
have shown that disrupting the function of telomerase
RNA leads to progressive shortening of telomeres, suggest-
ing that this component plays an essential role in telom-
erase function [18].
The genes coding for the RNA subunits of telomerase have
been cloned from a wide variety of species [12,19] and
have been shown to be essential for telomerase function
in vivo [18,20-23]. In humans, genes coding for hTERT
and hTR have been cloned and mapped to chromosomes
5p15.33 and 3q26.3 respectively [4,24].
Expression of hTERT was found to be at high levels in
malignant tumors and cancer cell lines but not in normal
tissues or telomerase-negative cell lines, and a strong cor-
relation was found between hTERT expression and telom-
erase activity in breast cancer [25].
We previously reported that telomerase reactivation was
significantly associated with advanced breast cancer stage,
histopathological grade [26] and nodal metastasis with
no significant association between telomerase activity and
menopausal status, or tumor size [27]. Furthermore, we
reported no significant association between tumour
hTERT expression and patient's age, tumour size, grade,
nodal metastasis, estrogen receptor (ER) positivity and
lymphovascular (LVI) [28,29].
The aim of this study was to examine the expression of tel-
omerase subunits hTERT and hTR and correlate them with
different clinical and pathological parameters including
tumour's size and grade, nodal status and patient's age in
human breast cancer.
Materials and methods
Patients
Institutional guidelines including ethical approval and
informed consent were followed. Samples from 46
patients with primary invasive breast cancer and 3
patients with benign breast lesions were studied. All
patients were surgically treated at (Day General Hospital,
Tehran, Iran) during 2004–2005. Breast tissues were col-
lected and preserved by rapid freezing in liquid nitrogen
immediately after surgical excision and then were stored
at -70°C.
RT-PCR analysis
Total RNA was isolated from samples using Tripure Isola-
tion Reagent (Roche, Germany). The mixture of one
microgram of total RNA, random hexamer and M-Mulv
reverse transcriptase enzyme (Fermentas Co, Canada) was
used to create cDNA for each sample, according to the
manufacturer's protocol. In order to avoid he probable
DNA contamination for RNA samples, the following
stages were performed. We prepared a solution containing
the same materials used for cDNA synthesis excluding
reverse transcriptase enzyme (negative control 1). This
product contains DNA only, with a new concentration
similar to the cDNA products. However, in the PCR prod-
ucts of these samples, the presence or absence of any DNA
contamination could be observed and detected.
In order to perform DNase treatment, 1 μg of total RNA
was digested by DNase (Fermentas Co, Canada) according
to the manufacturer's protocol. Half of DNase treated
RNA sample was used to create cDNA. The remaining half
of the sample contained all of the materials excluding the
reverse transcriptase enzyme (negative control 2), in order
to validate the accuracy of DNase treatment process.
The cDNA, DNase treated cDNA and control group sam-
ples (to evaluating the accuracy of DNase treatment) were
amplified in a 25 μl reaction mixture containing 0.2 μM
of each primers and 1U Taq DNA polymerase (Fermentas
Co, Canada). For detecting the accuracy of RNA extraction
and cDNA synthesis, phosphoglucomutase 1 (PGM1)
housekeeping gene was used in RT-PCR performance. The
sequence of oligonucleotides which were used for ampli-
fication of PGM1, hTR and hTERT genes is listed in table
1. Amplified products were subjected to electrophoresis in
2% agarose gels and were visualized with ethidium bro-
mide.
Statistical analysis
The statistical analysis of the data was carried out by using
the SPSS software package (SPSS Inc; Chicago, IL, USA;Page 2 of 5
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Exact test were performed for the analysis of probable con-
tributions. The significance levels were considered for
results with P value lower than 0.05.
Results
The mean age of patients with primary breast cancer at
diagnosis was 47 years with a range of (28–71). 22.2%
(10/45) of the patients were diagnosed at the age of 40 or
younger.
hTERT and hTR genes expression were detected in 38
(82.6%) and 31 (67.4%) breast cancers respectively (Fig-
ure 1) (Table 2). hTR gene was expressed in all cancers
from patients aged ≤ 40 years (10/10) compared to 60 %
(21/35) of patients aged > 40 years (p = 0.019). This sig-
nificant observation was not seen with hTERT. Further-
more, there was a significant association between hTERT
expression and hTR expression when comparing patients
aged ≤ 40 with those who are > 40 years old. (p = 0.018).
Tumour size range was (0.9–7.0 cm) with a mean of 2.67
cm. We observed no association between tumour size and
expression of hTR and hTERT (Table 3) Moreover, no
association was seen between hTR, hTERT expression and
tumour's grade, stage, axillary node status and pathologi-
cal type of the tumour.
Finally, two of the benign breast lesion showed hTERT
expression. However, none of them expressed hTR (Table
4).
Discussion
It is well established that telomerase activity requires the
presence of its subunits; hTR and hTERT. This study
focuses on a new angle in the understanding of telomerase
regulation in breast cancer. To our knowledge, this is the
first study to examine the association between hTR and
the prognostic factors in human breast cancer. We used
the DNase treatment method for the detection of hTR
gene expression in order to avoid DNA contamination in
RNA extracts. Such contamination may result in false pos-
itive findings when RT-PCR technique is used alone in
those genes that lack introns or contain pseudogene (such
as GAPDH housekeeping gene). Previous studies did not
perform the DNase treatment method prior to cDNA syn-
thesis. This resulted in hTR being expressed in both cancer
and benign cells alike, hence, very little attention was
given to hTR role in the telomerase regulation and corre-
lation with prognostic factors [30-39].
We found that benign breast lesions showed no expres-
sion of hTR. Such an observation agrees with other stud-
ies; Yashima et al showed that hTR expression in stromal
cells, including those in fibroadenomas, was negative and
increased hTR expression was observed in some foci of
apocrine metaplasia and atypical hyperplasia [40]. More-
over, a multistage tumorigenesis study in transgenic mice
has shown that the RNA component of telomerase is up-
regulated in the first stages of tumorigenesis, even in pre-
Table 2: hTR and hTERT expression in 46 malignant samples
hTR expression hTERT expression
Positive 67.4% (31) 82.6 %(38)
Negative 32.6 %(15) 17.4% (8)
Table 1: The oligonucleotide sequence of primers used for detecting expression of genes of interest, in the RT-PCR assay.
Oligonucleotide Sequence Amplified length Annealing temperature
PGM1–1718 5'-TCCGACTGAGCGGCACTGGGAGTGC-3' 386bp 63°C
PGM1–2080 5'-TCCGACTGAGCGGCACTGGGAGTGC-3'
hTR-F 5'-CGCCGTGCTTTTGCT CC-3' 316bp 63°C
hTR-R 5'-ACTCGCTCCGTTCCTCTTCC-3'
hTERT–13187 5'-CGG AAG AGT GTC TGG AGC AA-3' 145bp 67°C
hTERT–15411 '5'-TCC AGA CTC CGC TTC ATC C-3'
The electropherogram of the PGM1, hTR and hTERT genes RT-PCRFigur  1
The electropherogram of the PGM1, hTR and hTERT genes 
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may be a predictive marker for invasive tumor develop-
ment.
Our observation that hTR expression was associated with
younger age (patients aged ≤ 40 years) is a very interesting
one. This has implication regarding telomerase gene
based therapy or cancer treatment strategies in young
patients with breast cancer such as targeting the template
region of hTR with anti hTR (such as oligonucleotides)
which may inhibit cell telomerase activity and cell prolif-
eration and can lead to a profound induction of pro-
grammed cell death [41,42]
We conclude that hTR expression probably plays a greater
role in mammary tumourogenesis in younger women (≤
40 Years.). Tumours in older patients may develop telom-
erase independent mechanisms for survival.
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